Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Zillow Group Inc Class A (ZG) Price & Performance

Zillow Group Inc Class ATrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Zillow Group Inc Class A — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Sanofi SA is far larger — about 14.4× Zillow Group Inc Class A's market cap, and Sanofi SA pays a 6.01% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Zillow Group Inc Class A for 86 Days on average.

SNYZG
Market Cap
$95.18B$6.59B
Volume
2,995,6461,361,381
Sector
HealthMedia
52-Week High
$52.34$74.58
52-Week Low
$39.51$27.70
Typical Hold Time
94 Days86 Days
Enterprise Value
$114.48B$6.47B
Dividend Yield
6.01%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.

The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.

Zillow Group Inc Class A

Zillow Group (ZG) trades at $29.87, up 6.79% on the day, showing strong momentum despite mixed technical signals. The company has demonstrated improved financial performance with revenue growth from $2.2B in 2024 to $2.6B in 2025 and achieving profitability with $23M net income after three years of losses. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though Q4 2025 missed expectations. Analyst consensus remains divided with a Hold rating but offers significant upside potential with a $48.87 price target.

The outlook for ZG appears cautiously optimistic with fundamental improvement offset by housing market headwinds. Investment opportunity lies in the company's transition to profitability and market share gains in digital real estate, while risks include interest rate sensitivity, competitive pressures from Compass, and ongoing housing affordability challenges that could impact transaction volumes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SNY
35% Buy65% Sell
Avg holding period · 94 Days
ZG
100% Buy0% Sell
Avg holding period · 86 Days

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →

About Zillow Group Inc Class A

Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.

Read more on ZG →